For Patients

Clinical Trials

Avelas Biosciences has completed its Phase 1b clinical trial for AVB-620 in women with primary, non-recurrent breast cancer undergoing surgery.

The company expects to initiate a Phase 2 trial in the first half of 2017.

For further information, please email us at contact@avelasbio.com